Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update

    NEXT STORY
    UNITY Biotechnology, Inc. Announces Upcoming Scientific Presentations at ACR 2019 Annual Meeting
    PREV STORY
    Capnography Devices Market
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

    -  In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an ...

    author_avatar
    NASDAQ Market News

    Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

    author_avatar
    NASDAQ Market News

    Aftermath Services Launches 6th Annual K9 Grant

    AURORA, Ill., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Aftermath is officially kicking off its ...

    author_avatar
    NASDAQ Market News